Access cutting-edge small cell lung cancer treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access small cell lung cancer specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related small cell lung cancer treatment provided free
The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enrolling on the study will receive a
Sponsor: Hirva Mamdani
Check if you qualify for this small cell lung cancer clinical trial in Indianapolis, IN
If you're searching for small cell lung cancer treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.